Table 2.

Demographic, clinical and laboratory characteristics of HIV-infected adult participants newly diagnosed with Kaposi sarcoma at one of three medical facilities in East Africa for whom rapid case ascertainment was performed.

Characteristic	KS Cases (N=289)
Age, years	35 (30 to 42)*
Female gender	31%
Facility
AMPATH, Kenya	63%
Masaka-RRH, Uganda	26%
Mbarara-RRH, Uganda	12%
Monthly household income, USD	120 (50 to 270)
Number of anatomic sites with lesions †	6 (4 to 10)
Presence of edema ‡	81%
Antiretroviral therapy in use	88%
CD4+ T cells, cells/mm 3	246 (97 to 408)
HIV RNA in plasma, copies/ml
undetectable (<40)	43%
40–1,000	28%
1,001–10,000	8.8%
>10,000	20%
Hemoglobin, g/dl	11 (9 to 13)
ACTG T1 stage §	91%
ACTG S1 stage ¶	47%

^*median (interquartile range)

^†Sites included head, oral cavity, neck, chest, abdomen, back, right upper extremity, left upper extremity, right lower extremity, and left lower extremity. Maximum number of sites is 10.

^‡Swelling in any of the following sites: faces, genitals, and upper and lower extremities.

^§One or more of the following: edema; nodular oral lesions; and visceral involvement other than in lymph nodes [1].

^¶One or more of the following: opportunistic infections; one or more B symptoms; Karnofsky performance status score < 70; and any other HIV-related illness [1]

AMPATH denotes Academic Model Providing Access to Healthcare in western Kenya; Masaka-RRH denotes Masaka Regional Referral Hospital Uganda Cares in Masaka, Uganda; and Mbarara-RRH denotes Mbarara Regional Referral Hospital, Immune Suppressive Syndrome clinic in Mbarara, Uganda. ACTG denotes AIDS Clinical Trials Group.